甲氨蝶呤治疗中、重度银屑病的疗效观察  

Methotrexate in the treatment of patients with moderate to severe psoriasis

作　　者：李常兴 张锡宝[2] 黄振明[2] 刘玉梅[2] 吴志华[3] 陈秋霞[3] 

机构地区：[1]东莞市慢性病防治院皮肤科,广东东莞523008 [2]广州市皮肤病防治所,广东广州510095 [3]广东医学院附属医院皮肤科,广东湛江524001

出　　处：《临床皮肤科杂志》2006年第5期327-328,共2页Journal of Clinical Dermatology

基　　金：广东省医学科学技术研究基金资助项目(A2004581);广东省重点科学技术攻关项目(99050)

摘　　要：目的:观察甲氨蝶呤(methotrexate,MTX)治疗中、重度银屑病的临床疗效和安全性。方法:41例银屑病患者每周接受MTX5～15mg静脉滴注治疗1次,共20次。结果:41例患者经过10～20周治疗后,痊愈16例(39.0%),显效17例(41.5%),好转7例(17.1%),无效1例(2.4%),有效率为80.5%,不良反应为纳差、恶心、呕吐、头痛、荨麻疹、月经过多、丙氨酸转氨酶轻度升高。结论:MTX5～15mg每周1次静脉滴注治疗中、重度银屑病安全有效。Objective： To study the clinical effect of methotrexate（MTX） in the treatment of patients with moderate to severe psoriasis. Methods： Forty-one outpatients were treated with MTX 5mg-15mg/w for 10 to 20 weeks. Results： The results showed that the cured rate, effective rate and improvement rate were 39.0%, 41.5% and 17.1%, respectively. Adverse effects of MTX include nausea, vomiting, headache, urticaria, menometrorrhagia and increase of alanine aminotransferase. Conclusion： This study indicates that MTX is effective in the treatment of patient with moderate to severe psoriasis.

关 键 词：银屑病 甲氨蝶呤 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]